enGene closes business combination with SPAC Forbion European Acquisition Corp., becomes public on Nasdaq

enGene Therapeutics Inc.

New enGene shares and warrants trade on Nasdaq under 'ENGN' and 'ENGNW' starting Nov 1, 2023.
Approximately 10.4 million FEAC Class A shares were redeemed in connection with the deal.
Post-combination, Forbion Growth (31.9%), Lumira Ventures (14.4%), and others are top shareholders.
Company retains enGene's focus on non-viral gene therapies for mucosal tissues, lead candidate EG-70 for NMIBC.
PIPE financing was consummated alongside the transaction (amount not disclosed in this filing).

item 1.01 item 2.01 item 9.01 item 3.02 item 3.03 item 5.01 item 5.02 item 5.03 item 5.05 item 5.06

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

enGene Therapeutics Inc.: FEAC and New enGene ceased to be shell companies upon closing of business combination (effective 2023-10-31).

Change: shell status
Effective: 2023-10-31

Exact text from the filing

On October 31, 2023, as a result of the consummation of the Business Combination, each of FEAC and New enGene ceased to be a shell company.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

enGene Therapeutics Inc.: Adopted new Code of Business Conduct and Ethics on October 31, 2023 (effective 2023-10-31).

Change: code of ethics
Effective: 2023-10-31

Exact text from the filing

on October 31, 2023, New enGene’s board of directors approved and adopted a new Code of Business Conduct and Ethics

View on SEC.gov

101 governance changes filed in the last 30 days. Browse all governance changes →

enGene Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-267243

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.